28 enrolling by invitation. 28 Phase 2, 6 Phase 3, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 28 | Enrolling by invitation 28 |
| Phase 3 | 6 | Enrolling by invitation 6 |
| Phase 1 | 5 | Enrolling by invitation 5 |
Follow Musculoskeletal Diseases: new trials by email Literature Review of Musculoskeletal Diseases trials Research Report on Musculoskeletal Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Post-Radiofrequency Corticosteroid Injection on the Incidence of Post-Neurotomy Neuritis Dexamethasone, Normal Saline, Bupivacaine - Facet Joint Pain, Arthropathy | Phase 2 | Enrolling by invitation | Siriraj Hospital | 126 | 2026-10-01 | 2026-09-28 |
| TLL-018 in Patients With Moderate to Severe Active Rheumatoid Arthritis With Inadequate Response or Intolerance to csDMARDs TLL-018, Placebo - Rheumatoid Arthritis (RA) | Phase 2 | Enrolling by invitation | Hangzhou Highlightll Pharmaceutical Co., Ltd | 90 | 2026-09-18 | 2026-09-28 |
| Setmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a) Setmelanotide - Pseudohypoparathyroidism Type 1a, Obesity | Phase 2 | Enrolling by invitation | Massachusetts General Hospital | 1 | 2026-07-21 | 2026-07-23 |
| The Effect of Osteoporotic Medications on Vertebral Bone Quality Score Abaloparatide - Lumbar Degenerative Disease | Phase 2 | Enrolling by invitation | State University of New York at Buffalo | 60 | 2026-06-18 | 2026-07-23 |
| Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia Infigratinib - Hypochondroplasia | Phase 2 | Enrolling by invitation | QED Therapeutics, a BridgeBio company | 135 | 2026-04-23 | 2026-08-26 |
| An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of BMN 351 in Participants With Duchenne Muscular Dystrophy BMN 351 - Duchenne Muscular Dystrophy (DMD) | Phase 2 | Enrolling by invitation | BioMarin Pharmaceutical | 18 | 2026-04-20 | 2026-07-24 |
| Knee Pain Ejiao Paste for Knee Osteoarthritis Knee Pain Ejiao Paste, Knee Pain Ejiao-free Clear Paste - Knee Osteoarthritis | Phase 2 | Enrolling by invitation | ShuGuang Hospital | 60 | 2026-03-30 | 2026-06-05 |
| Open-Label Extension Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy WVE-N531 - Duchenne Muscular Dystrophy | Phase 2 | Enrolling by invitation | Wave Life Sciences USA, Inc. | 175 | 2025-12-28 | 2026-03-06 |
| Electromagnetic Immunotherapy Mapping and Cytokine Forecasting Study (QSIT) Low-Frequency Electromagnetic Resonance Therapy (LF-EMR), Sham Resonance Device (Inactive Control), Low-Dose Naltrexone (LDN) - Systemic Lupus Erythematosus, Rheumatoid Arthritis | Phase 1 / Phase 2 | Enrolling by invitation | Truway Health, Inc. | 120 | 2025-10-23 | 2026-05-22 |
| An Open-label Long-term Follow-up Study of SAT-3247 for Participants With Duchenne Muscular Dystrophy Including Those Who Participated in SAT-3247-CL-101 SAT-3247 - Duchenne Muscular Dystrophy (DMD) | Phase 2 | Enrolling by invitation | Satellos Bioscience, Inc. | 30 | 2025-08-20 | 2026-10-13 |
| Efficacy Test of Curcuminoid Standardized Turmeric Capsules to Improving Inflammatory Biomarkers in Osteoarthritis Genu Curcuminoid Standardized Turmeric Capsules, Placebo - Osteoarthritis | Phase 2 / Phase 3 | Enrolling by invitation | Gadjah Mada University | 72 | 2025-06-01 | 2025-09-19 |
| 124I-Evuzamitide PET/CT Imaging In Patients With Lumbar Spinal Stenosis and Carpal Tunnel Syndrome 124I-evuzamitide - Lumbar Spinal Stenosis, Carpal Tunnel Syndrome (CTS) | Phase 2 | Enrolling by invitation | University of Tennessee Graduate School of Medicine | 40 | 2025-05-22 | 2026-07-21 |
| A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I VX-670 - Myotonic Dystrophy Type 1 (DM1) | Phase 2 | Enrolling by invitation | Vertex Pharmaceuticals Incorporated | 44 | 2025-04-28 | 2026-10-14 |
| An Interventional Study of Infigratinib in Children With Hypochondroplasia infigratinib 0.128 mg/kg/day, infigratinib 0.25 mg/kg/day - Hypochondroplasia | Phase 2 / Phase 3 | Enrolling by invitation | QED Therapeutics, a BridgeBio company | 24 | 2025-04-22 | 2026-07-16 |
| The Effectiveness of CBD and CBN in the Treatment of Facial Pain and Headache of Muscular Origin An aqueous solution containing CBD and CBN, The aqueous solution of placebo - Myalgia, Muscle Pain | Phase 2 / Phase 3 | Enrolling by invitation | Wroclaw Medical University | 42 | 2025-04-01 | 2026-03-06 |
| Mesenchymal Stem Cells Infusion in Patients With Autoimmune Diseases Mesenchymal Stem Cells, Placebo - Rheumatoid Arthritis, Systemic Lupus Erythematosus (SLE) | Phase 1 / Phase 2 | Enrolling by invitation | National Institute of Blood and Marrow Transplant (NIBMT), Pakistan | 200 | 2025-02-01 | 2025-03-21 |
| Evaluating the Accuracy of Soft Tissue Prediction in Patients With Mandibular Prognathism After Orthognathic Surgery Using Handheld Scanner Versus Optical Scanner A Prospective Clinical Trial face scanning pre and post orthognathic surgery - Mandibular Prognathism, Orthognathic Surgery | Phase 1 / Phase 2 | Enrolling by invitation | Cairo University | 11 | 2024-09-24 | 2024-12-09 |
| Orthobiologic Treatment for Knee Osteoarthritis PRP injection, ADSTEM Inj. (Adult human mesenchymal stem cells), Injection - Osteoarthritis Knee | Phase 2 / Phase 3 | Enrolling by invitation | University Hospital of North Norway | 160 | 2024-09-23 | 2026-06-15 |
| Study of SRP-1001 in Adult and Adolescent Participants With Facioscapulohumeral Muscular Dystrophy Type 1 SRP-1001 for Injection, Placebo - Muscular Dystrophy, Facioscapulohumeral | Phase 1 / Phase 2 | Enrolling by invitation | Sarepta Therapeutics, Inc. | 60 | 2024-06-19 | 2026-10-05 |
| Fecal Microbiome Transplantation From Healthy Donors to Individuals With Fibromyalgia Fecal Microbiome Transplantation, Sham Fecal Microbiome Transplantation - Fibromyalgia | Phase 2 | Enrolling by invitation | Rambam Health Care Campus | 100 | 2024-03-11 | 2024-05-21 |
Showing 20 of 28. Sign in to see all of them.
Genetic Diseases, Inborn (4) · Muscular Dystrophy, Duchenne (4) · Arthritis, Rheumatoid (3) · Bone Diseases (3) · Dwarfism (3) · Mucopolysaccharidosis IV (3) · Osteochondrodysplasias (3) · Achondroplasia (2) · Autoimmune Diseases (2) · Chronic Pain (2) · Hypochondroplasia (2) · Lupus Erythematosus, Systemic (2) · Myotonic Dystrophy (2) · Osteoarthritis (2)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (15) · Nervous System Diseases (12) · Muscular Diseases (11) · Genetic Diseases, Inborn (10) · Neuromuscular Diseases (10) · Bone Diseases (7) · Joint Diseases (7) · Metabolic Diseases (7) · Nutritional and Metabolic Diseases (7) · Rheumatic Diseases (7) · Arthritis (6) · Connective Tissue Diseases (6) · Metabolism, Inborn Errors (6) · Muscular Disorders, Atrophic (6)
infigratinib (3) · Injections (2) · Bupivacaine (1) · Cannabinol (1) · Dexamethasone (1) · Fecal Microbiota Transplantation (1) · Naltrexone (1) · Saline Solution (1) · Sodium Chloride (1) · abaloparatide (1) · setmelanotide (1)
QED Therapeutics, a BridgeBio company (3) · Sarepta Therapeutics, Inc. (2) · Wroclaw Medical University (2) · Ascendis Pharma Growth Disorders A/S (1) · BioMarin Pharmaceutical (1) · Cairo University (1) · Edgewise Therapeutics, Inc. (1) · Gadjah Mada University (1) · Hangzhou Highlightll Pharmaceutical Co., Ltd (1) · Jaclyn Tamaroff (1) · Lumos Pharma (1) · Massachusetts General Hospital (1) · National Institute of Blood and Marrow Transplant (NIBMT), Pakistan (1) · Rambam Health Care Campus (1) · Satellos Bioscience, Inc. (1)
United States (14) · Australia (10) · Spain (9) · United Kingdom (9) · Canada (7) · France (6) · Germany (5) · Italy (5) · Netherlands (4) · New Zealand (4) · Norway (4) · Belgium (3) · Portugal (3) · Singapore (3) · China (2)
Amir Minerbi, MD-PhD (1) · Emily B. Martin, PhD (1) · Gavin Solomon, President & CEO (1) · Jaclyn Tamaroff, MD (1) · Joanne M. Donovan, MD, PhD (1) · Memoona Haider, MBBS, FCPS (1) · Mieszko Wieckiewicz, Prof. (1) · Mohab Ibrahim, Md., Ph.D (1) · Mohamed Ahmed Farid, Professor of OMFS (1) · Sameh Tarek Mekhemar, Head of Department (1) · Yuelong Cao, Ph.D (1) · Zeng Xiaofeng Zeng, PhD (1)
2023 (1)